Media, investors, advocacy organizations and others, please contact us here.
For US healthcare professionals only
The purpose of this Travere Therapeutics Medical Affairs website is to support healthcare professionals with scientific information. This website is also a channel for US healthcare professionals to submit questions or connect with Travere Therapeutics US healthcare professionals. The information provided is for educational purposes only and is not intended to promote any products. By continuing to use this site you are acknowledging that you are a US healthcare professional
Newly Administered Immunosuppressive Therapy (IST) Has No Impact on Long-term Antiproteinuric Effect of Sparsentan (SPAR), a Dual Angiotensin and Endothelin Receptor Antagonist, in Patients With Primary Focal Segmental Glomerulosclerosis (FSGS): Interim Analysis of the Phase 2 DUET Trial
Long-term Effects of Sparsentan, a Dual Angiotensin and Endothelin Receptor Antagonist in Primary Focal Segmental Glomerulosclerosis (FSGS): Interim 84-Week Analysis of the DUET Trial
Antiproteinuric Effect of Sparsentan, A Dual Angiotensin II and Endothelin Type A Receptor Antagonist, in Patients With Primary Focal Segmental Glomerulosclerosis (FSGS): A Subgroup Analysis of the DUET Trial
Long-Term Effect of Sparsentan (SPAR), a Dual Angiotensin and Endothelin Receptor Antagonist, on Proteinuria in Patients with Primary FSGS: Interim Analysis of the DUET Trial